Biologically adaptive radiotherapy for oropharyngeal cancer

HS Greater Glasgow and Clyde0 个研究点目标入组 20 人开始时间: 2022年11月2日最近更新: 2024年3月25日

适应症

试验速览

暂无简介。

•1. Histologically confirmed HPV-negative oropharyngeal squamous cell carcinoma (OPSCC) or HPV-positive OPSCC and significant smoking history (>20 pack years) within the past 20 years
•2. Stage III, IVa or IVb OPSCC
•3. Scheduled for single modality photon radiotherapy as primary radical treatment
•4.18 years old and over
•5. Able to give informed consent
•6. Patients willing and able to comply with the protocol for the duration of the study

•1. Head and neck cancers from sub-sites other than oropharynx
•2. HPV-positive oropharyngeal squamous cell carcinoma (OPSCC) in patients with no significant smoking history (low-risk OPSCC)
•3. Confirmed distal metastatic disease (stage IVc)
•4. Patients who have undergone primary surgery for OPSCC (including neck dissection)
•5. Patients who have received induction chemotherapy prior to definitive treatment
•6. Patients receiving chemoradiotherapy or cetuximab-radiotherapy
•7. Prior radiotherapy to the head and neck region
•8. Patients with contra-indications to MRI scanning
•9. Patients who do not adequately understand verbal or written information

发起方

HS Greater Glasgow and Clyde